



New Insights into Personalized Medicine for Ophthalmic Disease: From Mechanism to Therapy

Guest Editor:

Prof. Dr. Adriana Elena

Bulboaca

Pathophysiology Department,
Universitatea de Medicina si
Farmacie Iuliu Hatieganu din
Cluj-Napoca, Cluj Napoca,
Romania

Deadline for manuscript
submissions:

closed (5 November 2023)

Message from the Guest Editor

Nanotechnology continues to progress and to contribute to a modern approach towards patients from diagnosis methods to therapeutic options. The clinical applications and the molecular diagnosis in ophthalmology have been limited and the therapies are expected to be personalized. There is a high clinical need for new experimental efficient therapies to be implemented for patient benefits. There are real scientific progresses in mechanisms involved in the discovery of ocular surface disorders therapies, retinal disease pathology, glaucoma or neurooftalmology. Therapies with anti-vascular endothelial growth factor have resulted in enhanced outcomes for a variety of retinal disease. Molecular mechanisms' applications for personalized treatments can increase efficacy and improve the outcome in the majority of eye disease.

This Special Issue aims to focus on the latest research progress of the molecular bases of eye diseases and the relevant signalling pathways, as well as advanced techniques that help the diagnosis and in establishing personalized treatments. Authors are welcome to submit both articles and review papers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA

2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)